NextCure Past Earnings Performance
Past criteria checks 0/6
NextCure's earnings have been declining at an average annual rate of -14.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 74.8% per year.
Key information
-14.8%
Earnings growth rate
-6.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -74.8% |
| Return on equity | -77.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NextCure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -59 | 16 | 44 |
| 30 Jun 24 | 0 | -61 | 17 | 47 |
| 31 Mar 24 | 0 | -64 | 19 | 48 |
| 31 Dec 23 | 0 | -63 | 20 | 48 |
| 30 Sep 23 | 0 | -66 | 21 | 49 |
| 30 Jun 23 | 0 | -70 | 22 | 51 |
| 31 Mar 23 | 0 | -70 | 21 | 51 |
| 31 Dec 22 | 0 | -75 | 22 | 54 |
| 30 Sep 22 | 0 | -74 | 22 | 92 |
| 30 Jun 22 | 0 | -73 | 21 | 78 |
| 31 Mar 22 | 0 | -73 | 21 | 53 |
| 31 Dec 21 | 0 | -69 | 21 | 50 |
| 30 Sep 21 | 0 | -68 | 20 | 0 |
| 30 Jun 21 | 0 | -66 | 20 | 0 |
| 31 Mar 21 | 0 | -63 | 18 | 12 |
| 31 Dec 20 | 22 | -37 | 17 | 0 |
| 30 Sep 20 | 24 | -32 | 16 | 0 |
| 30 Jun 20 | 26 | -24 | 13 | 0 |
| 31 Mar 20 | 27 | -18 | 12 | 0 |
| 31 Dec 19 | 6 | -34 | 10 | 0 |
| 30 Sep 19 | 4 | -30 | 8 | 0 |
| 30 Jun 19 | 3 | -27 | 6 | 0 |
| 31 Mar 19 | 1 | -24 | 4 | 0 |
| 31 Dec 18 | 0 | -23 | 3 | 0 |
Quality Earnings: 2US is currently unprofitable.
Growing Profit Margin: 2US is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2US is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare 2US's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2US is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2US has a negative Return on Equity (-77.41%), as it is currently unprofitable.